Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhejiang Univ. FGFR4 compound C3
- Development stage
- Unknown
- Lead developer
- Zhejiang University
01
Overview
Zhejiang Univ. FGFR4 compound C3: sourced facts only. name: "Among them, a novel compound (C3) showed FGFR4 and cell proliferation inhibitory activity." [PMID:35217375]; target: "Among them, a novel compound (C3) showed FGFR4 and cell proliferation inhibitory activity." [PMID:35217375]; developer: "Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR China." [PMID:35217375]
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on Zhejiang Univ. FGFR4 compound C3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Univ. FGFR4 compound C3.